Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics

  1. Carmen Capone
  2. Fabrice Dabertrand
  3. Celine Baron-Menguy
  4. Athena Chalaris
  5. Lamia Ghezali
  6. Valérie Domenga-Denier
  7. Stefanie Schmidt
  8. Clément Huneau
  9. Stefan Rose-John
  10. Mark T Nelson
  11. Anne Joutel  Is a corresponding author
  1. INSERM, France
  2. University of Vermont, United States
  3. Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Germany
  4. University of Vermont, University of Manchester, United States

Abstract

Cerebral small vessel disease (SVD) is a leading cause of stroke and dementia. CADASIL, an inherited SVD, alters cerebral artery function, compromising blood flow to the working brain. TIMP3 (tissue inhibitor of metalloproteinase 3) accumulation in the vascular extracellular matrix in CADASIL is a key contributor to cerebrovascular dysfunction. However, the linkage between elevated TIMP3 and compromised cerebral blood flow (CBF) remains unknown. Here, we show that TIMP3 acts through inhibition of the metalloprotease ADAM17 and HB-EGF to regulate cerebral arterial tone and blood flow responses. In a clinically relevant CADASIL mouse model, we show that exogenous ADAM17 or HB-EGF restores cerebral arterial tone and blood flow responses, and identify upregulated voltage-dependent potassium channel (KV) number in cerebral arterial myocytes as a heretofore-unrecognized downstream effector of TIMP3-induced deficits. These results support the concept that the balance of TIMP3 and ADAM17 activity modulates CBF through regulation of myocyte KV channel number.

Article and author information

Author details

  1. Carmen Capone

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Fabrice Dabertrand

    Department of Pharmacology, University of Vermont, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Celine Baron-Menguy

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Athena Chalaris

    Molecular Biology of Cytokines, Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  5. Lamia Ghezali

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Valérie Domenga-Denier

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Stefanie Schmidt

    Molecular Biology of Cytokines, Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  8. Clément Huneau

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Stefan Rose-John

    Molecular Biology of Cytokines, Institute of Biochemistry, Medical Faculty, Christian Albrechts University, Kiel, Germany
    Competing interests
    The authors declare that no competing interests exist.
  10. Mark T Nelson

    Department of Pharmacology, University of Vermont, University of Manchester, Burlington, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Anne Joutel

    Genetics and Pathophysiology of Cerebrovascular Diseases, INSERM, Paris, France
    For correspondence
    anne.joutel@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3963-3860

Funding

Agence Nationale de la Recherche (ANR Genopath 2009-RAE09011HSA and ANR Blanc 2010-RPV11011HHA)

  • Anne Joutel

Fondation Leducq (Transatlantic Network of Excellence on the Pathogenesis of Small Vessel Disease of the Brain)

  • Mark T Nelson
  • Anne Joutel

European Union (Horizon 2020 research and innovation programme SVDs@target, grant agreement No 666881)

  • Mark T Nelson
  • Anne Joutel

National Institute of Health (R37DK053832, PO1HL095488, RO1HL44455, R01HL121706, R01HL131181)

  • Mark T Nelson

Totman Medical Research Trust

  • Mark T Nelson

United Leukodystrophy Foundation (CADASIL Research Grant)

  • Fabrice Dabertrand

Deutsche Forschungsgemeinschaft (DFG, SFB877 project A1 and the Cluster of Excellence Inflammation at Interfaces)

  • Athena Chalaris
  • Stefan Rose-John

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All experiments were conducted in full accordance with the French guidelines for the use of animals in research and were approved by the "Lariboisière-Villemin" Institutional Animal Care and Use Committee (C2EA 09), with every effort made to minimize the number of animals used.

Copyright

© 2016, Capone et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,928
    views
  • 434
    downloads
  • 60
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Carmen Capone
  2. Fabrice Dabertrand
  3. Celine Baron-Menguy
  4. Athena Chalaris
  5. Lamia Ghezali
  6. Valérie Domenga-Denier
  7. Stefanie Schmidt
  8. Clément Huneau
  9. Stefan Rose-John
  10. Mark T Nelson
  11. Anne Joutel
(2016)
Mechanistic insights into a TIMP3-sensitive pathway constitutively engaged in the regulation of cerebral hemodynamics
eLife 5:e17536.
https://doi.org/10.7554/eLife.17536

Share this article

https://doi.org/10.7554/eLife.17536

Further reading

    1. Neuroscience
    Jakob Rupert, Dragomir Milovanovic
    Insight

    By influencing calcium homeostasis, local protein synthesis and the endoplasmic reticulum, a small protein called Rab10 emerges as a crucial cytoplasmic regulator of neuropeptide secretion.

    1. Neuroscience
    Brian C Ruyle, Sarah Masud ... Jose A Morón
    Research Article

    Millions of Americans suffering from Opioid Use Disorders face a high risk of fatal overdose due to opioid-induced respiratory depression (OIRD). Fentanyl, a powerful synthetic opioid, is a major contributor to the rising rates of overdose deaths. Reversing fentanyl overdoses has proved challenging due to its high potency and the rapid onset of OIRD. We assessed the contributions of central and peripheral mu opioid receptors (MORs) in mediating fentanyl-induced physiological responses. The peripherally restricted MOR antagonist naloxone methiodide (NLXM) both prevented and reversed OIRD to a degree comparable to that of naloxone (NLX), indicating substantial involvement of peripheral MORs to OIRD. Interestingly, NLXM-mediated OIRD reversal did not produce aversive behaviors observed after NLX. We show that neurons in the nucleus of the solitary tract (nTS), the first central synapse of peripheral afferents, exhibit a biphasic activity profile following fentanyl exposure. NLXM pretreatment attenuates this activity, suggesting that these responses are mediated by peripheral MORs. Together, these findings establish a critical role for peripheral MORs, including ascending inputs to the nTS, as sites of dysfunction during OIRD. Furthermore, selective peripheral MOR antagonism could be a promising therapeutic strategy for managing OIRD by sparing CNS-driven acute opioid-associated withdrawal and aversion observed after NLX.